This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ACVRL1 · Western blot design guide
ACVRL1 Western Blot Planning Guide
Plan an ACVRL1 Western blot around the catalog-observed 56.1 kDa band, image-backed A01468-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
ACVRL1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 56.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Gallbladder | |
| Negative control | Bronchus |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 56.1 kDa |
| ⓘ | Localization | Cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated ACVRL1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Caudate |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A01468-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected ACVRL1 Western Blot Band Size?
Use the product-observed 56.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 56.1 kDa | Matches the authoritative product WB observation. |
| 56.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected ACVRL1 appearancePlan around 56.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 56.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 56.1 kDa from UniProt P37023; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A01468-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 56.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing ACVRL1 band
A01468-2 · ACVRL1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for ACVRL1 Western blot
🧪Use Gallbladder as the first positive-control candidate and Bronchus as the HPA Not detected negative candidate.
Positive control: Gallbladder (High)
Negative control: Bronchus (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for ACVRL1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Gallbladder | Reported tissue cells | High | Protein (HPA) | HPA → |
| Caudate | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebral cortex | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced ACVRL1 Western Blot Tips
Deeper troubleshooting and optimisation questions for ACVRL1, answered from its protein features.
Which band should guide the blot?
Use 56.1 kDa, the observation attached to the authoritative A01468-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 56.1 kDa expectation.
Which positive control should I start with?
Start with Gallbladder, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bronchus as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for ACVRL1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01468-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
ACVRL1 Western Blot Reagents
Human/Mouse/Rat-reactive ACVRL1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-ALK-1/ACVRL1 Antibody Picoband®
Cat # A01468-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P37023
- Human Protein Atlas — ACVRL1
- A01468-2 product record
- PMC3584037 — An intron mutation in the ACVRL1 may be associated with a transcriptional regulation defect in a Chinese family with hereditary hemorrhagic telangiectasia (PloS one, 2013)
- PMC10518977 — ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization (BMC medicine, 2023)
